Marlo Hargrave, NP
Family · Newport, ARNPI 1275041923
Payments from drug & device makers
Across 176 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$954
- Otsuka America Pharmaceutical, Inc.$284
- Novo Nordisk$215
- Amgen$183
- GSK$178
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$159
- plus $810 from 20 others
What the payments were for
- Food & beverage$2,783100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $954 |
| Otsuka America Pharmaceutical, Inc. | 14 | $284 |
| Novo Nordisk | 12 | $215 |
| Amgen | 13 | $183 |
| GSK | 11 | $178 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $159 |
| E.r. Squibb & Sons, L.L.C. | 2 | $140 |
| AstraZeneca | 5 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| Novartis | 4 | $67 |
| Lilly USA, LLC | 4 | $63 |
| Boehringer Ingelheim | 4 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Abbott | 2 | $36 |
| Lundbeck LLC | 2 | $34 |
| Astellas Pharma US Inc | 2 | $34 |
| Almatica Pharma LLC | 1 | $30 |
| Eisai Inc. | 2 | $28 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Genentech USA, Inc. | 2 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Cardiovascular Systems Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$115
How this compares
$2,783 in reported general payments places this provider in the 85th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 182 | $206,984 |
| OzempicSemaglutide | 158 | $160,198 |
| JardianceEmpagliflozin | 106 | $87,788 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $73,501 |
| EliquisApixaban | 96 | $70,043 |
| VraylarCariprazine Hcl | 24 | $47,301 |
| FarxigaDapagliflozin Propanediol | 52 | $39,228 |
| EntrestoSacubitril/Valsartan | 47 | $34,926 |
| RexultiBrexpiprazole | 18 | $30,187 |
| JanuviaSitagliptin Phosphate | 39 | $28,856 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $19,724 |
| MyrbetriqMirabegron | 25 | $19,259 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 51 | $17,633 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $17,255 |
| XareltoRivaroxaban | 30 | $16,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Insulin Lispro | $63 | $209,480193 claims |
| Novo NordiskOzempic | $215 | $160,198158 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Synjardy Xr | $56 | $102,005134 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $178 | $76,983108 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $80 | $56,48470 claims |
| AbbVieVraylar, Linzess | $954 | $55,53739 claims |
| NovartisEntresto | $67 | $34,92647 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $284 | $30,18718 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $19,25925 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $42 | $10,71014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,103 family providers in Arkansas.
Other family in Newport
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.